As part of the transaction, the company has acquired 32.75% stake in Satiya Nutraceuticals on a fully diluted basis and requisite majority control over its board composition and total voting rights. Accordingly, it has become a subsidiary of the company and the acquisition of remaining stake of 25.25% on a fully diluted basis will be completed in tranches by May 2025, subject to terms and conditions of the definitive agreements.
